Drug intelligence / Profile preview

VRC-EBODNA023-00-VP

Development stage: Phase 1
Lead developer: Vaccine Research Center
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-EBODNA023-00-VP is a second-generation DNA vaccine developed as a prophylactic vaccine against Ebola virus infection. It consists of two closed-circular plasmids, each encoding the wild-type glycoprotein (GP) from two different Ebola virus species: Zaire ebolavirus and Sudan-Gulu ebolavirus. The vaccine is designed to induce an immune response by expressing these viral glycoproteins in the recipient, thereby stimulating protective immunity without containing any live or inactivated virus. The primary mechanism of action involves the inhibition of Ebola virus entry into host cells by generating antibodies targeting the viral glycoproteins. Developed by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), this candidate has undergone Phase 1 clinical trials to assess its safety and immunogenicity in healthy adults[5][7][8][9].

Other names: Ebola DNA plasmid vaccineVRC Ebola DNA vaccine

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on VRC-EBODNA023-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-EBODNA023-00-VP.

Explore the full profile